Abemaciclib was used on the basis of homozygous CDKN2A/B deletion according to the results of the interim analysis of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (Wen et al. 2020). Here, CDKN2A is linked to glioblastoma.